Within the department of Immunology & Microbiology at The Scripps Research Institute, the following postdoctoral position is available:
Principal Investigator: Philippe Gallay
Hepatitis B virus (HBV) infection is a major health burden worldwide with 240 million chronically infected individuals. Nucleos(t)ide analogs and interferons are the current standards of care due to their suppression of HBV replication, but the treatments fail to eradicate HBV from individuals. Therefore, new strategies are absolutely required to cure HBV. Our laboratory recently identified a novel approach showing solid premises to provide such a cure.
Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide, accounting for over half a million deaths per year. Chronic infections with hepatitis B (HBV) and C (HCV) viruses have been recognized as main human liver carcinogens. Multiple non-viral factors have also been implicated in the development of HCC. The development of non-alcoholic steatohepatitis (NASH) and liver fibrosis represent high risk factors for HCC. Remarkably, we recently found that cyclophilin inhibitors suppress the development of viral-induced and non-viral-induced liver fibrosis and HCC in mouse models. However, their mechanisms of action are totally unknown.
Positions: A postdoctoral position is immediately available to study the cure of HBV using in vivo and in vitro HBV infectious models and to study the protective effects of cyclophilin inhibitors in liver damage mouse models.
Possess a recent (less than one year) Ph.D. in immunology, virology, microbiology, or a relevant field from a credited university or institute. A pending doctoral degree (to be obtained in a few months) is also considered.
Have a good publishing record with first-author papers.
Have some cell culture experience
Experience with mice would be a plus.
Please send CV and three professional references to firstname.lastname@example.org.
Internal Number: 3291963
About The Scripps Research Institute
Dr. Gallay is Professor, Department of Immunology and Microbial Science at the Scripps Research Institute in La Jolla (San Diego), California. Dr. Gallay holds a Swiss Federal Diploma (MS), from the Institute of Biochemistry, Epalinges, Switzerland and a PhD from Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Dr. Gallay’s research program examines the molecular basis of HIV, HCV, and HBV pathogenesis, including characterization of host proteins modulating viral replication, such as various cyclophilins (Host Targeting Antivirals). In particular, Dr. Gallay has studied the role of cyclophilin inhibition on disease progression, and has investigated cyclophilin-NS5A complexes, viral mutations, and synergism with other antiviral compounds, including the Direct Acting Antivirals. Dr. Gallay has presented his research at numerous scientific and research symposia worldwide. He serves as a reviewer for more than 40 journals, has served as a Member on the Center for AIDS Research Developmental Grant Review Committee, and has served as an ad hoc member of the National Institute of Allergy and Infectious Diseases (NIAID), the Medical Research Council (MRC, UK), as well as a...n ad hoc member of similar committees in Netherlands, Austria, and Switzerland. Dr. Gallay has more than 95 peer-reviewed publications.